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While the prevalence of X4-tropic viruses in subtype B
is relatively well studied the distribution of tropism in
CRF06_cpx (causing Estonian epidemic) is less known,
especially in the treatment experienced patients with
established multidrug-resistance and who are candidates
for therapy with CCR5 antagonist.
Aim: to describe HIV-1 drug resistance mutations
(DRMs) and co-receptor tropism in antiretroviral (ARV)
treatment failing patients infected with HIV-1
CRF06_cpx and to establish their suitability to treatment
with CCR5 receptor antagonists.
Altogether 12 patients were studied – all with ARV
therapy failure and considered to start CCR5 antagonist
therapy. Genomic viral DNA was directly sequenced in
pol region and V3 loop of gp120 in triplicates. HIV-1
DRMs and tropism were detected using Stanford Univer-
sity Drug Resistance Database and Geno2pheno[coreceptor]
2.5. algorithm, respectively. All sequence prediction
results with a false-positivity rate above 10% were consid-
ered R5-tropic.
Of 12 viruses 11 were successfully sequenced and ana-
lyzed. Patients have been diagnosed and ARV therapy
initiated in 2002-2013. 8/11 cases had failure of the sec-
ond ARV regimen, 4/11 of the third and in 2/11 of the
fourth ARV regimen. Median viral load at the time of
tropism testing was 53,326 (IQR 16,328-113,018) and
median CD4+ count 184 (IQR 142-217) cells/cmm. The
most commonly used regimens were EFV + 3TC plus
AZT (5 cases) or plus ABC (4 cases). Of 11 viruses 10
had resistance against two ARV classes (NRTI + NNRTI
or NNRTI + INI) and 1 had triple class resistance
(NRTI + NNRTI + PI). In NRTI treated population the
most common primary DRM was M184V (10/11),
followed by L74V/IL/I and K70E/R/EKQ (both 4/11). In
NNRTI treated population DRMs were as follows:
K103N (5/11), P225H (4/411), G190A/S and K101H/E
(both 3/11), others were seen in lower frequency. In PI
treated patients two primary DRMs were represented –
I54V, V82A (both in same case). In INI treated population
one primary DRM was represented – Y143R. The majority
of viruses (10/11) were R5-tropic and all determined as
CRF06_cpx by phylogenetic analysis.
The Estonian HIV epidemic has reached the stage
where the first patients are considered to start treatment
with CCR5 antagonists. Almost all highly resistant viruses
were R5-tropic suggesting that CCR5 antagonists are an
appropriate option for CRF06_cpx viruses resistant to
other ARV agents.
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